Perceptive Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Perceptive Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,132	Closed	-$739K	–	136
2018 Q1	$739K	Buy	+9,132	New	+$703K	0.02%	115
2016 Q2	–	Sell	-17,507	Closed	-$514K	–	183
2016 Q1	$514K	Buy	+17,507	New	+$487K	0.05%	120
2015 Q3	–	Sell	-4,956	Closed	-$223K	–	164
2015 Q2	$223K	Buy	+4,956	New	+$193K	0.01%	157
2014 Q4	–	Sell	-3,040	Closed	-$120K	–	158
2014 Q3	$120K	Buy	+3,040	New	+$121K	0.01%	103

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors's ENTA Position: Q2 2018 in Review

Perceptive Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2018, closing a stake of 9,132 shares — an estimated $739K sold.

Perceptive Advisors first reported a position in ENTA in Q3 2014 and held it in 4 quarters. The position peaked at $739K in Q1 2018. 193 funds tracked by Wall St. Rank hold ENTA as of Q2 2018.

Perceptive Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Perceptive Advisors sold 9,132 Enanta Pharmaceuticals shares in Q2 2018, an estimated $739K.
Perceptive Advisors first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Perceptive Advisors's Enanta Pharmaceuticals position peaked at $739K in Q1 2018.
193 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.